Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Bergamo
Clinical trial register · Italy

Clinical Trials in Bergamo, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Italy and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 6778 matching records held by the registry are in this view. Synced 08 Oct 2026, 03:19 UTC
6778
Studies in scope
all four open statuses
4069
Recruiting now
open to new participants
1018
Lead sponsors
across recruiting studies
Top sites
Milan 138 Naples 80 Roma 72 Florence 57 Padova 56
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca32 Hoffmann-La Roche16 Janssen Research & Development, LLC15 Mario Negri Institute for Pharmacological Research14 Novartis Pharmaceuticals13 Clear sponsor filter
Site location
Milan138 Naples80 Roma72 Florence57 Padova56
All 111 locations
Target enrolment
to

Trials with a site in Bergamo

32 of 6778 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Italy
Start
Recruiting
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
NCT07761117Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
DrugElecoglipron
AstraZeneca
Phase 3
6,950
Ancona, Bergamo, Brescia, Milan, Pavia, Perugia, Riccione, Salerno
2026-08-24
Recruiting
AstraZeneca
Phase 3
150
Aviano, Bergamo, Genova, Milan, Naples
2026-06-15
Recruiting
AstraZeneca
Phase 1/2
152
Bergamo, Meldola, Milan, Roma
2026-06-03
Recruiting
AstraZeneca
Observational
200
Ancona, Bergamo, Foggia, Meldola, Milan, Modena, Naples, Padova
2026-04-16
Recruiting
AstraZeneca
Observational
335
Salerno, Padova, Teramo, Treviso, Varese, Bari, Bergamo, Bologna
2025-12-20
Recruiting
AstraZeneca
Phase 3
700
Arezzo, Bari, Bergamo, Chieti, Genoa, Milan, Naples, Palermo
2025-08-06
Active, closed
AstraZeneca
Observational
315
Cittadella (PD), Montebelluna (TV), Aosta, Avellino, Bari, Bergamo, Brescia, Cagliari
2025-06-25
Recruiting
AstraZeneca
Phase 3
15,100
Altamura, Arzignano, Bergamo, Bologna, Brescia, Caserta, Catania, Cona
2025-06-04
Recruiting
AstraZeneca
Phase 3
400
Bari, Bergamo, Brescia, Cagliari, Catanzaro, Genoa, Milan, Modena
2025-03-28
Recruiting
AstraZeneca
Phase 3
11,300
Alessandria, Bari, Bergamo, Brescia, Chiavari, Cona, Foggia, Milan
2025-03-14
Recruiting
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
NCT06535607Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy), Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy), Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)
DrugsVolrustomig·Adrucil·Paclitaxel·Cisplatin
AstraZeneca
Phase 2
257
Alessandria, Bergamo, Orbassano
2024-08-22
Recruiting
AstraZeneca
Phase 3
788
Bergamo, Bologna, Milan, Modena, Naples, Padova, Reggio Emilia, Rome
2024-08-01
Recruiting
AstraZeneca
Phase 3
3,850
Acquaviva delle Fonti, Bari, Bergamo, Brescia, Catania, Catanzaro, Cona, Cortona
2024-04-12
Recruiting
AstraZeneca
Phase 3
675
Bergamo, Genoa, Milan, Monza, Padova, Pavia, Ravenna, Roma
2024-04-11
Recruiting
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
NCT06137118B-cell Acute Lymphoblastic Leukemia (B-ALL)
DrugSurovatamig
AstraZeneca
Phase 1/2
255
Bergamo, Bologna, Monza, Naples, Roma
2023-12-29
Recruiting
AstraZeneca
Phase 3
625
Bergamo, Empoli, Milan, Modena, Naples, Padova, Reggio Emilia, Roma
2023-11-23
Active, closed
AstraZeneca
Phase 3
863
Alessandria, Bari, Bergamo, Milan, Monza, Orbassano, Padova, Parma
2023-11-09
Active, closed
AstraZeneca
Phase 3
1,835
Bergamo, Bologna, Foggia, Genoa, Naples, Pisa, Roma, Torino
2023-11-07
Active, closed
AstraZeneca
Phase 3
895
Bari, Bergamo, Milan, Padova, Parma, Pavia, Ravenna, Roma
2023-10-24
Active, closed
AstraZeneca
Phase 3
5,511
Bergamo, Bologna, Florence, Genoa, Meldola, Milan, Misterbianco, Monza
2023-10-05
Active, closed
AstraZeneca
Phase 3
791
Bergamo, Roma, Rozzano
2022-02-18
Active, closed
AstraZeneca
Phase 3
315
Bergamo, Bologna, Florence, Meldola, Milan, Misterbianco, Naples, Padova
2021-06-30
Active, closed
AstraZeneca
Phase 3
506
Ancona, Bergamo, Catania, Milan, Naples, Padova, Prato
2021-06-22
Active, closed
AstraZeneca
Phase 3
1,157
Bergamo, Candiolo, Genova, Livorno, Milan, Naples, Padova, Rozzano
2021-04-26
Active, closed
AstraZeneca
Phase 3
1,371
Bergamo, Florence, Milan, Modena, Naples, Novara, Padova, Parma
2021-01-28
Active, closed
AstraZeneca
Phase 3
866
Aviano, Bergamo, Candiolo, Cona, Genova, Livorno, Messina, Milan
2020-07-24
Active, closed
AstraZeneca
Phase 3
818
Bergamo, Candiolo, Catanzaro, Livorno, Meldola, Milan, Modena, Naples
2020-04-16
Active, closed
AstraZeneca
Phase 3
825
Ancona, Bari, Bergamo, Florence, Milan, Monza, Padova, Roma
2018-12-06
Active, closed
AstraZeneca
Phase 3
987
Bergamo, Meldola, Milan, Palermo, Roma, Terni
2017-03-27
Active, closed
AstraZeneca
Phase 3
682
Bari, Bergamo, Bologna, Cremona, Florence, Lucca, Meldola, Milan
2015-10-21
Active, closed
AstraZeneca
Phase 3
1,837
Bergamo, Bologna, Bolzano, Castellanza Varese, Lecce, Legnago, Milan, Modena
2014-04-22
Active, closed
AstraZeneca
Phase 3
736
Aviano, Bergamo, Carpi, Genova, Prato, Reggio Emilia, Varese
2005-02-13
Rows per page Showing 1–32 of 32
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Italian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 10 October 2026. https://priyalifescience.com/clinical-trials-italy/city/bergamo

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Italy and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 6,778 studies in total at the last sync on 08 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 32 of those studies with a site in Bergamo that also match the filters currently applied.

How many clinical trials are recruiting in Bergamo?

15 of the 32 studies on this page are recruiting new participants as of the 08 Oct 2026, 03:19 UTC sync. A further 0 have not yet opened recruitment, 17 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Bergamo), 32 studies
PhaseStudiesRecruitingShare
Phase 3261081.3%
Observational329.4%
Phase 1/2226.3%
Phase 2113.1%

Most active sponsors

Lead sponsors with the most studies (Bergamo)
Lead sponsorStudiesRecruiting
AstraZeneca3215
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.